Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO’s analysis of tumor microenvironment
Source: itnonline.com